全国首个原液境内分段生产试点进口生物制品获批

新京报05-21

5月21日，强生旗下全人源新生儿Fc受体（FcRn）拮抗剂安力威（尼卡利单抗注射液）获国家药监局批准，联合常规治疗药物用于治疗全身型重症肌无力。　　重症肌无力（MG）是一种自身免疫性疾病，患者的免疫系统错误地产生抗体，这些抗体可作用于神经-肌肉接头处，阻断或干扰神经向肌肉的正常信号传导，从而影响或阻止肌肉收缩。该病可发生于男女各年龄段及各种族和族群，但多在年轻女性和老年男性中发病。早期症状通常以...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2637335371?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-21 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637335371","market":"us","top_or_hot":-1,"title":"全国首个原液境内分段生产试点进口生物制品获批","media":"新京报","content":"<div>\n<p>5月21日，强生旗下全人源新生儿Fc受体（FcRn）拮抗剂安力威（尼卡利单抗注射液）获国家药监局批准，联合常规治疗药物用于治疗全身型重症肌无力。　　重症肌无力（MG）是一种自身免疫性疾病，患者的免疫系统错误地产生抗体，这些抗体可作用于神经-肌肉接头处，阻断或干扰神经向肌肉的正常信号传导，从而影响或阻止肌肉收缩。该病可发生于男女各年龄段及各种族和族群，但多在年轻女性和老年男性中发病。早期症状通常以...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605213745430486.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>全国首个原液境内分段生产试点进口生物制品获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n全国首个原液境内分段生产试点进口生物制品获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-21 20:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202605213745430486.html><strong>新京报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月21日，强生旗下全人源新生儿Fc受体（FcRn）拮抗剂安力威（尼卡利单抗注射液）获国家药监局批准，联合常规治疗药物用于治疗全身型重症肌无力。　　重症肌无力（MG）是一种自身免疫性疾病，患者的免疫系统错误地产生抗体，这些抗体可作用于神经-肌肉接头处，阻断或干扰神经向肌肉的正常信号传导，从而影响或阻止肌肉收缩。该病可发生于男女各年龄段及各种族和族群，但多在年轻女性和老年男性中发病。早期症状通常以...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202605213745430486.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z4B17.USD","symbol_name":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202605213745430486.html","article_id":"2637335371","we_media_id":null,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605213745430486.html","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637335371","pubTimestamp":1779365040,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"5月21日，强生旗下全人源新生儿Fc受体（FcRn）拮抗剂安力威（尼卡利单抗注射液）获国家药监局批准，联合常规治疗药物用于治疗全身型重症肌无力。重症肌无力（MG）是一种自身免疫性疾病，患者的免疫系统错误地产生抗体，这些抗体可作用于神经-肌肉接头处，阻断或干扰神经向肌肉的正常信号传导，从而影响或阻止肌肉收缩。该病可发生于男女各年龄段及各种族和族群，但多在年轻女性和老年男性中发病。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","MG":"Mistras Group","BK4123":"调查和咨询服务","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"China's first domestic staged production pilot of bulk solution imported biological products was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MG":1},"content_text":"5月21日，强生旗下全人源新生儿Fc受体（FcRn）拮抗剂安力威（尼卡利单抗注射液）获国家药监局批准，联合常规治疗药物用于治疗全身型重症肌无力。　　重症肌无力（MG）是一种自身免疫性疾病，患者的免疫系统错误地产生抗体，这些抗体可作用于神经-肌肉接头处，阻断或干扰神经向肌肉的正常信号传导，从而影响或阻止肌肉收缩。该病可发生于男女各年龄段及各种族和族群，但多在年轻女性和老年男性中发病。早期症状通常以眼部表现为主，但约85%的患者会进展为全身型重症肌无力（gMG），可表现为严重肌无力，并可能伴随言语和吞咽困难等症状。目前针对该疾病仍存在未满足的临床需求，需要能提供持续平稳疾病控制、且具有明确安全性的有效疗法。　　作为一种FcRn拮抗剂，安力威可显著降低免疫球蛋白G（IgG）水平，这些IgG抗体是全身型重症肌无力的主要致病因素，同时不对其他适应性免疫和先天免疫功能产生可检测的额外影响。该新药上市申请获得了国家药监局药品审评中心的优先审评审批资格，同时也是全国首个获批开展原液境内分段生产试点的进口生物制品。该药品原液在国内生产，制剂和包装在境外生产。（文章来源：新京报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637335371","isCrawlerRequest":true}